Prognostic influence of paravalvular leak following TAVI: is aortic regurgitation an active incremental risk factor or just a mere indicator?

Affiliations

¹ Cardiovascular Surgery Clinic, Herzzentrum, UniversitätsSpital Zürich, Zürich, Switzerland Francesco.Maisano@usz.ch.
² Cardiovascular Surgery Clinic, Herzzentrum, UniversitätsSpital Zürich, Zürich, Switzerland.
³ Cardiology Clinic, Herzzentrum, UniversitätsSpital Zürich, Zürich, Switzerland.

Editorial

Francesco Maisano et al. Eur Heart J. 2015.

. 2015 Feb 14;36(7):413-5.

doi: 10.1093/eurheartj/ehu410. Epub 2014 Oct 21.

¹ Cardiovascular Surgery Clinic, Herzzentrum, UniversitätsSpital Zürich, Zürich, Switzerland Francesco.Maisano@usz.ch.
² Cardiovascular Surgery Clinic, Herzzentrum, UniversitätsSpital Zürich, Zürich, Switzerland.
³ Cardiology Clinic, Herzzentrum, UniversitätsSpital Zürich, Zürich, Switzerland.

No abstract available

Comment on

Paravalvular regurgitation after transcatheter aortic valve replacement with the Edwards sapien valve in the PARTNER trial: characterizing patients and impact on outcomes.
Kodali S, Pibarot P, Douglas PS, Williams M, Xu K, Thourani V, Rihal CS, Zajarias A, Doshi D, Davidson M, Tuzcu EM, Stewart W, Weissman NJ, Svensson L, Greason K, Maniar H, Mack M, Anwaruddin S, Leon MB, Hahn RT. Kodali S, et al. Eur Heart J. 2015 Feb 14;36(7):449-56. doi: 10.1093/eurheartj/ehu384. Epub 2014 Oct 1. Eur Heart J. 2015. PMID: 25273886 Clinical Trial.